ARK Invest's position in BEAM, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 7,890,875 | $189.6M | 2.60% | #14 |
| ARKG | 3,201,266 | $76.9M | 3.90% | #10 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-30 | ARKG | Buy | Added | 22,687 | $618K |
| 2026-10-29 | ARKG | Buy | Added | 36,201 | $1.0M |
| 2026-10-28 | ARKG | Buy | Added | 4,497 | $129K |
| 2026-10-27 | ARKG | Buy | Added | 91,527 | $2.3M |
| 2026-10-13 | ARKG | Buy | Added | 49,090 | $1.2M |
| 2026-10-12 | ARKG | Buy | Added | 65,154 | $1.6M |
| 2026-10-09 | ARKG | Buy | Added | 19,510 | $501K |
| 2026-09-23 | ARKG | Buy | Added | 65,553 | $1.6M |
| 2026-09-22 | ARKG | Buy | Added | 9,519 | $247K |
| 2026-09-21 | ARKG | Buy | Added | 102,565 | $2.6M |
| 2026-09-09 | ARKK | Buy | Added | 197,922 | $5.0M |
| 2026-09-09 | ARKG | Buy | Added | 73,237 | $1.8M |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid…
See BEAM's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open BEAM on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.